abeona therapeutics inc. (nasdaq: $abeo), is a leading clinical-stage biopharmaceutical company focused on developing novel gene therapies for life-threatening rare genetic diseases. abeona was forged from the company’s close collaborations with key stakeholders all dedicated to transforming new biotechnology insights into breakthrough treatments for rare diseases. abeona's lead programs include abo-102 (aav-sgsh), an adeno-associated virus (aav) based gene therapy for sanfilippo syndrome type a (mps iiia) and eb-101 (gene-corrected skin grafts) for recessive dystrophic epidermolysis bullosa (rdeb). abeona is also developing abo-101 (aav-naglu) for sanfilippo syndrome type b (mps iiib), abo-201 (aav-cln3) gene therapy for juvenile batten disease (jncl), abo-202 (aav-cln1) for treatment of infantile batten disease (incl), eb-201 for epidermolysis bullosa (eb), abo-301 (aav-fancc) for fanconi anemia (fa) disorder and abo-302 using a novel crispr/cas9-based gene editing approach to gene t

ac immune is a clinical-stage swiss-based biopharmaceutical company, listed on nasdaq, which aims to become a global leader in precision medicine for neurodegenerative diseases. the company designs, discovers and develops therapeutic as well as diagnostic products intended to prevent and modify diseases caused by misfolding proteins. ac immune’s two proprietary technology platforms create antibodies, small molecules and vaccines designed to address a broad spectrum of neurodegenerative indications, such as alzheimer’s disease (ad). the company’s pipeline features nine therapeutic and three diagnostic product candidates – with five product candidates currently in clinical trials. the most advanced of these is crenezumab, a humanized anti-amyloid-β monoclonal igg4 antibody that targets monomeric and aggregated forms of amyloid-β, with highest affinity for neurotoxic oligomers. crenezumab is currently in two phase 3 clinical studies for ad, under a global program conducted by the collabor

accuray incorporated (nasdaq: aray) is a radiation oncology company that develops, manufactures and sells precise, innovative tumor treatment solutions that set the standard of care with the aim of helping patients live longer, better lives. the company's leading-edge technologies deliver the full range of radiation therapy and radiosurgery treatments. for more information, please visit www.accuray.com. for career opportunities, please visit http://www.accuray.com/careers.

the aethlon medical (nasdaq:aemd) mission is to create innovative devices that address unmet medical needs in cancer, infectious disease, and other life-threatening conditions. our aethlon adapt™ platform provides the technology foundation for a new class of therapeutics that target the selective removal of disease enabling particles from the entire circulatory system. the aethlon adapt™ product pipeline includes the hemopurifier®, a first-in-class medical device with broad-spectrum capabilities against exosomes that contribute to the progression of cancer and infectious viral pathogens such as hiv and hepatitis c.

agile therapeutics is a forward-thinking women's healthcare company dedicated to fulfilling the unmet health needs of today's women. our product candidates are designed to provide women with contraceptive options that offer freedom from taking a daily pill, without committing to a longer-acting method. our lead product candidate, twirla®, (ethinyl estradiol and levonorgestrel transdermal system), also known as ag200-15, is a once-weekly prescription contraceptive patch that recently completed phase 3 trials. twirla is based on our proprietary transdermal patch technology, called skinfusion®, which is designed to provide advantages over currently available patches and is intended to optimize patch adhesion and patient wearability. for more information, please visit the company website at www.agiletherapeutics.com. connect with us on twitter at @agilether.

air transport services group, inc. provides air cargo transportation and related services to domestic and foreign air carriers and other companies that outsource their air cargo lift requirements. through its principal subsidiaries, including three airlines with separate and distinct u.s. faa part 121 air carrier certificates, atsg provides air cargo lift, aircraft leasing, aircraft maintenance services, airport ground services, fuel management, specialized transportation management, and air charter brokerage services. major subsidiaries include - abx air, inc. (www.abxair.com) - air transport international llc (www.airtransport.cc) - capital cargo international airlines, inc. (www.capitalcargo.com) - airborne maintenance & engineering services, inc. (www.airbornemx.com) - airborne global services, inc.

founded in 2014 by experienced industry leaders and scientists from university of california at santa barbara (ucsb) and cornell university, akoustis’ mission is to commercialize and manufacture its patent-pending bulk one™ acoustic wave technology to address the critical frequency-selectivity requirements in today’s mobile smartphones – improving the efficiency and signal quality of mobile wireless devices and enabling the internet of things. the bulk acoustic wave (baw) filter market is rapidly expanding, driven by growth in 4g/lte and the number of filters required per device. nearly 2 billion mobile phones are manufactured per year, and over half are in the growing segment of high-end smartphones. because these smartphones need to operate globally, on more than one carrier, and with bands that are becoming ever-closer together, the need for higher-performance filters is upon us to ensure mobile compatibility. 4g/lte networks are driving the need for higher frequencies, and traditio

alimera, founded in june 2003, is a pharmaceutical company that specializes in the research, development and commercialization of prescription ophthalmic pharmaceuticals. alimera is presently focused on diseases affecting the back of the eye, or retina, because these diseases are not well treated with current therapies and will affect millions of people in aging populations. alimera's commitment to retina specialists and their patients is manifest in its product and in its development portfolio designed to treat early- and late-stage diseases. for more information, please visit www.alimerasciences.com. alimera's european operations are conducted from london by its subsidiary, alimera sciences limited.

allied motion technologies inc. is a u.s. public company focused exclusively on serving the motion control market. allied motion is listed on the nasdaq stock market; symbol: amot. we design and manufacture motor and servo motion products for the commercial, industrial, and aerospace and defense markets. allied motion is growing both internally and through acquisition, and we intend to be a leading worldwide supplier of technically advanced motion control products to our selected market segments.